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Clinical question: What is the best treatment for bacterial conjunctivitis?
Results: Topical antibiotics expedite recovery from bacterial conjunctivitis. The choice of 
antibiotic usually does not affect outcome.
Implementation: Recognition of key distinguishing features of bacterial conjunctivitis
•	 Pitfalls that can be recognized in the history and physical examination
•	 Choice of antibiotic
•	 When to refer for specialist treatment.
Keywords: bacterial conjunctivitis, topical antibiotics
Bacterial conjunctivitis
Definition: Bacterial conjunctivitis is inflammation of the conjunctiva as a result of bacterial 
infection.
Etiology: Most commonly Staphylococcus species in adults, and Streptococcus pneumonia and 
the Gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis in children. 
Contact lens wearers are at particular risk for Gram-negative infections. such as Pseudomonas 
aeruginosa. Neisseria gonorrhoeae is primarily a neonatal etiology.
Incidence: One recent study estimates an annual incidence rate of 135 per 10,000 in the US.1
Economics: The same study found the estimated total direct and indirect cost of treating bacterial 
conjunctivitis in the US to be $589 million annually. Accounting for a 20% variation in annual inci-
dence rate and treatment cost resulted in an estimated cost range of $377 to $857 million per year.
Level of evidence used in this summary: Systematic reviews, meta-analyses, and random-
ized controlled trials from 1990 to 2010.
Search sources: Ovid MEDLINE, PubMed, Cochrane Library, NHS evidence, Clinical 
Evidence.
Outcomes: From the patient perspective, the main outcomes are:
1.  Speed of symptomatic resolution
2.  Convenience of treatment
3.  Avoidance of complications.
Consumer summary: Bacterial conjunctivitis is inflammation of the conjunctiva caused 
by direct contact with infected secretions. The most common organisms are Staphylococcus 
species, S. pneumonia, H. influenzae, and M. catarrhalis. It presents with conjunctival injection, 
mucopurulent discharge, and crusty eyelids. The diagnosis is usually clinical. The condition is 
often self-limiting, but there is good evidence that antibiotics improve remission rates. Most of Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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the current evidence suggests that the choice of topical antibiotics and 
the treatment regimen do not significantly affect the rate of recovery 
The evidence
Table 1 randomized controlled trials comparing antibiotics with placebo
Author Number of patients 
randomized
Interventions Outcome measures Results
Abelson et al4 279 One group received azithromycin  
One group received “vehicle”
Clinical resolution  
and bacterial eradication
Higher rate of microbial and 
clinical cure with antibiotic.
Everitt et al5 307 Two groups received chloramphenicol 
One group received placebo
Symptomatic relief Antibiotic decreased the 
duration of symptoms.
Hwang et al6 249 One group received levofloxacin
One group received placebo
Clinical resolution  
and bacterial eradication
Higher rate of microbial  
and clinical cure  
with antibiotic.
Karpecki et al7 269 One group received besifloxacin 
One group received “vehicle”
Clinical resolution  
and bacterial eradication
Higher rate of microbial and 
clinical cure with antibiotic
Leibowitz8 177 One group received ciprofloxacin 
One group received placebo
Culture results Higher rate of microbial cure 
with antibiotic.
Lichtenstein and  
rinehart9
167 One group received levofloxacin 
One group received ofloxacin
One group received placebo
Clinical resolution  
and bacterial eradication
Higher rate of microbial and 
clinical cure with antibiotics.
Miller et al10 284 One group received norfloxacin 
One group received placebo
Bacterial eradication  
and clinical resolution
Higher rate of microbial and 
clinical cure with antibiotic.
rietveld et al11 181 One group received fusidic acid 
One group received placebo
Clinical resolution  
and bacterial eradication
no difference in clinical 
recovery rate but higher rate 
of microbial eradication with 
antibiotic
rose et al12 326 One group received chloramphenicol 
One group received placebo
Clinical cure by day 7 No significant difference 
between antibiotic and placebo
Tepedino et al13 957 One group received besifloxacin 
One group received “vehicle”
Clinical resolution  
and bacterial eradication
Higher rate of microbial and 
clinical cure with antibiotic
from infection. Failure to recognize and treat bacterial conjunctivitis 
may lead to complications, such as keratitis or anterior uveitis.
Do any interventions make a difference to 
the resolution of bacterial conjunctivitis?
Systematic reviews:  2
Meta-analyses:  1
Randomized controlled trials:  10
The Cochrane systematic review,2 which includes a 
meta-analysis, concluded that “acute bacterial conjuncti-
vitis is frequently a self-limiting condition, but the use of 
antibiotics is associated with significantly improved rates 
of clinical and microbiological remission”. The system-
atic review by Clinical Evidence3 concludes that topical 
antibiotics are   “beneficial” in people with culture-positive 
nongonococcal bacterial conjunctivitis and “likely to be 
beneficial” when used empirically in people with suspected 
bacterial conjunctivitis within 1–2 days if symptoms do not 
resolve on their own. Oral antibiotics, ocular decongestants, 
warm compresses, and saline were found to be of “unknown 
effectiveness”.
Most randomized controlled trials (see Table 1) showed 
that topical antibiotics accelerate bacterial eradication 
and help resolve the signs and symptoms of bacterial 
conjunctivitis. However, in two trials,4,5 clinical recovery 
at seven days after presentation was found to be unaffected 
by the use of antibiotics, even though one of the two tri-
als4 still found an improvement in microbial cure rate with 
antibiotics.
Which antibiotics are best for accelerating 
resolution of bacterial conjunctivitis?
Systematic reviews:  1
Meta-analyses:  0
Randomized controlled trials:  26
Table 2 lists the antibiotics studied, along with their 
microbial coverage, mechanism of action, and availability. 
The systematic review3 concluded that “there is no clear 
best choice for topical antibiotics – local microbiological 
resistance patterns, cost, dosing regimens, and other patient 
factors (such as allergies and compliance) are important con-
siderations in addition to efficacy”. Results from randomized 
controlled trials (Table 3) are varied, but many found similar Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Table 2 Topical antibiotics used to treat bacterial conjunctivitis
Antibiotic Class Coverage Mechanism Availability
Azithromycin Macrolide Broad-spectrum Baceriostatic Azasite® 1% (inspire  
Pharmaceuticals inc)
Besifloxacin Fluoroquinolone Broad-spectrum Bactericidal Besivance® 0.6% (Bausch  
and Lomb)
Chloramphenicol Chloramphenicol Broad-spectrum Bacteriostatic Topical drops not marketed in US
Optrex infected Eyes® 0.5% in UK
Ciprofloxacin Fluoroquinolone Broad-spectrum Bactericidal Ciloxan® 0.3% (Alcon Laboratories inc) 
Ointment or drops
Fusidic acid Protein synthesis 
inhibitor
Primarily Gram-positive Bacteriostatic not available in US 
Fucithalmic® 1% (Leo Pharma) in 
Canada and UK
Gatifloxacin Fluoroquinolone Broad-spectrum Bactericidal Zymar 0.3% (Allergan inc)
Gentamicin Aminoglycoside Primarily Gram-negative Bactericidal Generic 0.3% drops
Levofloxacin Fluoroquinolone Broad-spectrum Bactericidal iquix® 1.5% (vistakon Pharmaceuticals)
Lomefloxacin Fluoroquinolone Broad-spectrum Bactericidal not available in US
Moxifloxacin Fluoroquinolone Broad-spectrum Bactericidal vigamox® 0.5% (Alcon Laboratories inc)
neomycin-polymyxin  
B-gramicidin
Aminoglycoside,  
polymyxin and gramicidin
Broad-spectrum Bactericidal neosporin® (King Pharmaceuticals inc)
netilmicin Aminoglycoside Primarily Gram-negative Bactericidal not available in US
Norfloxacin Fluoroquinolone Broad-spectrum Bactericidal Chibroxin 0.3% (Merck and Co inc) 
not available in US
Ofloxacin Fluoroquinolone Broad-spectrum Bactericidal Generic 0.3% eye drops
Providone-iodine Broad-spectrum Bactericidal Betadine 5% (Alcon Laboratories inc)
rifamycin rifamycin Broad-spectrum Bactericidal not available in US
Tobramycin Aminoglycoside Primarily Gram-negative Bactericidal Tobrex® 0.3% (Alcon Laboratories inc) 
ointment or drops
Table 3 randomized controlled trials comparing different topical antibiotics
Author Number of  
randomized  
patients
Interventions Outcome  
measures
Results
Adenis at al14 131 0.3% ciprofloxacin  
versus 0.3% norfloxacin
Clinical resolution  
and bacterial eradication
no difference between the  
two antibiotics
Adenis et al15 41 0.3% ciprofloxacin  
versus 1% rifamycin
Clinical resolution  
and bacterial eradication
Higher clinical cure rate with 
ciprofloxacin on day 7 (but below 
statistical significance: P = 0.061), 
no difference in microbial cure
Bloom et al16 464 Ciprofloxacin versus  
tobramycin
Clinical resolution  
and bacterial eradication
no difference between the  
two antibiotics
Bremond-Gignac et al17 150 1.5% azithromycin  
versus 0.3% tobramycin
Clinical resolution  
and bacterial eradication
Greater bacteriologic cure 
with azithromycin on day 3, 
no difference in clinical or 
bacteriologic cure on day 9
Chisari et al18 190 Ciprofloxacin versus  
norfloxacin
Clinical resolution  
and bacterial eradication
no difference between the  
two antibiotics
Cochereau et al19 1043 1.5% azithromycin for  
3 days versus 0.3%  
tobramycin for 7 days
Clinical resolution  
and bacterial eradication
Higher rate of clinical cure 
with azithromycin on day 3, 
no difference in clinical or 
bacteriologic cure on day 9
Denis et al20 1043 1.5% azithromycin for  
3 days versus 0.3%  
tobramycin for 7 days
Microbiological resolution no difference between the  
two groups
Gallenga et al21 99 0.3% lomefloxacin BID  
versus 0.3% tobramycin QiD
Clinical resolution  
and bacterial eradication
no difference between the  
two groups
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Table 3 (Continued)
Author Number of  
randomized  
patients
Interventions Outcome  
measures
Results
Granet et al22 84 eyes of  
56 patients
Polymyxin/trimethoprim QiD  
versus 0.5% moxifloxacin TID
relief of signs  
and symptoms
Faster clinical resolution with 
moxifloxacin
Gwon23 345 0.3% ofloxacin  
versus 0.3% tobramycin
Clinical resolution  
and bacterial eradication
Similar efficacy between the  
two treatments, more rapid 
symptom relief with ofloxacin
isenberg et al24 459 total, 124  
culture-positive  
for bacteria
1.25% povidone-iodine  
versus neomycin-polymyxin  
B-gramicidin
Clinical resolution no difference between povidone-
iodine and antibiotic
Jackson et al25 484 1% fusidic acid  
versus 0.3% tobramycin
Clinical resolution,  
bacterial eradication,  
compliance, subjective 
“convenience” of treatment
no difference between clinical 
or microbial resolution, higher 
compliance and convenience  
with fusidic acid among  
younger patients
Kernt et al26 276 Enhanced-viscosity 0.3%  
tobramycin BiD versus 0.3% 
tobramycin QiD
Clinical resolution no difference between the  
two groups
Lichtenstein et al11 167 0.5% levofloxacin  
versus 0.3% ofloxacin  
(versus placebo)
Clinical resolution  
and bacterial eradication
Higher microbial eradication rate 
with levofloxacin in 2–11-year-old 
children; no difference between 
the two antibiotics in other age 
groups
Malminiemi et al27 45 0.3% lomefloxacin  
versus 1% fusidic acid
Clinical resolution  
and bacterial eradication
no difference in clinical recovery 
but higher rate of bacterial 
eradication with lomefloxacin  
after 3–5 days
McDonald et al28 1161 0.6% besifloxacin  
versus 0.3% moxifloxacin
Clinical resolution  
and bacterial eradication
no difference between the  
two groups; higher rate of eye 
irritation with moxifloxacin
Milazzo et al29 45 0.3% netilmicin  
versus 0.3% tobramycin
Clinical resolution  
and bacterial eradication
no difference in clinical resolution, 
better microbiologic outcome with 
netilmicin
Miller et al30 246 Norfloxacin versus  
chloramphenicol
Clinical resolution  
and bacterial eradication
no difference between the  
two groups
normann et al31 456 newborns 1% fusidic acid versus  
0.5% chloramphenicol
Clinical resolution  
and compliance
No difference in efficacy but better 
compliance with fusidic acid
Papa et al32 209 netilmicin versus  
gentamicin
Clinical resolution  
and bacterial eradication
Greater efficacy rate  
with netilmicin
Power et al33 ? 0.3% ciprofloxacin versus  
0.5% chloramphenicol
Clinical resolution  
and bacterial eradication
no difference between the  
two groups
Protzko et al34 743 1% azithromycin in  
DuraSite versus 0.3%  
tobramycin
Safety, clinical resolution  
and bacterial eradication
Similar safety and efficacy  
between the two groups
robert et al35 1043 1.5% azithromycin  
versus 0.3% tobramycin
Clinical resolution no difference between the  
two groups
Schwab et al36 423 0.5% levofloxacin  
versus 0.3% ofloxacin
Clinical resolution  
and bacterial eradication
More rapid microbial resolution 
with levofloxacin, similar clinical 
resolution
Tabbara et al37 40 0.3% lomefloxacin  
versus 0.3% ofloxacin
Clinical resolution no difference between the  
two groups
Zhang et al38 132 0.3% levofloxacin  
versus 0.3% ofloxacin
Clinical resolution  
and bacterial eradication
no difference between the  
two groups
Abbreviations: BiD, twice daily; TiD, three times daily; QiD, four times daily.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Table 4 randomized controlled trials comparing different regimens of treatment
Author Number of randomized  
patients
Interventions Outcome measures Results
Friedlaender39 50 0.3% ofloxacin BID versus QID Clinical resolution  
and bacterial eradication
no difference between 
the two groups
Szaflik et al40 120 0.5% levofloxacin TID × 5 days  
versus “standard regimen”  
(Q2H × 2 days, then Q4H × 3 days)
Clinical resolution  
and bacterial eradication
no difference between 
the two groups
Wald et al41 80 Oral cefixime + topical placebo  
versus topical polymyxin- 
bacitracin + oral placebo
Clinical resolution  
and bacterial eradication
no difference between 
the two groups
Yee et al42 104 0.3% gatifloxacin BID versus QID Clinical resolution, bacterial  
eradication and safety
no difference between 
the two groups
Abbreviations: Q2H, two hourly; Q4H, four hourly; BiD, twice daily; TiD, three times daily; QiD, four times daily.
The practice
clinical and microbiologic efficacy among the topical anti-
biotics used. Some studies found faster bacterial eradication 
and/or clinical recovery with fluoroquinolones, azithromycin, 
or netilimicin compared with the more traditional antibiotics, 
such as tobramycin or polymyxin B/trimethoprim or gentami-
cin. Some studies found differences in patient compliance 
with different antibiotics. Microbiologic resistance patterns 
can also vary and would affect efficacy rates.
Which treatment regimen works best for 
bacterial conjunctivitis?
Systematic reviews:  0
Meta-analyses:  0
Randomized controlled trials:  4
A few randomized controlled trials (Table 4) have focused 
on the effect of the treatment regimen, such as dosing, fre-
quency, length of treatment, and route of administration, on 
efficacy rates. None have found a significant change in cure 
rate in association with the treatment regimen used.
Conclusions
Bacterial conjunctivitis often resolves on its own, but the cur-
rent evidence suggests that topical antibiotics help accelerate 
recovery from this self-limiting disease. Topical antibiotics 
used for treatment of bacterial conjunctivitis have similar 
efficacy rates. The treatment regimen does not affect recovery 
from bacterial conjunctivitis. Patients may prefer a simpler 
regimen.
there may be itching, chemosis, or conjunctival 
papillae
•	 Ask about contact lens wear
•	 Assess for corneal involvement and intraocular 
involvement
•	 Conjunctival swabs can be done for Gram stain, culture, 
and sensitivity to clarify diagnosis, particularly in more 
severe or refractory cases
•	 Moderate to severe eye pain, photophobia, or change 
in visual acuity should raise suspicion for more serious 
causes.
Treatment
•	 Uncomplicated cases can be treated with a topical anti-
biotic such as tobramycin, trimethoprim/polymyxin B, 
a fluoroquinolone or chloramphenicol four times daily 
for 5–7 days to accelerate recovery
•	 Patients should be seen every 2–3 days until signs and 
symptoms are resolved
Potential pitfalls
•	 Contact lens wearers are predisposed to Gram-negative 
infections, carrying a higher risk of complications, such 
as bacterial keratitis. Pseudomonas and Acanthamoeba 
infections in contact lens wearers can lead to serious, 
sight-threatening complications if not recognized and 
treated appropriately. The contact lens storage case may 
be the nidus of the infection.
•	 If there is an associated keratitis or anterior uveitis, refer-
ral to a specialist may be recommended
•	 Beware of combination topical antibiotic agents that 
contain steroids. These should be used with extreme 
caution and monitored by a specialist.
Management
Bacterial conjunctivitis can be managed by nonspecialists.
Assessment
•	 Redness, foreign body sensation and purulent/
mucopurulent discharge are common complaints; Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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•	 Failure to respond to topical antibiotics may warrant 
referral to a specialist.
indications for specialist referral
•	 Change in visual acuity
•	 Evidence of keratitis and/or anterior uveitis on slit-lamp 
examination
•	 Moderate-to-severe eye pain
•	 Failure to improve or worsening of symptoms in spite of 
treatment.
Further reading
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